Selected Posters and Abstracts
Nevirapine (Viramune) [NNRTI]
Nevirapine vs efavirenz in 742 patients: the liver toxicity of nevirapine is not linked to the female sex and a baseline CD4 count above 250 cells/L
R Manfredi
and L Calza.
Different rates of early viral load reduction with nevirapine or lopinavir/ritonavir-based combination antiretroviral therapies in pregnant women  
C Bell and others.
The efficacy of nevirapine in combination with two nucleoside analogues in the treatment of HIV patients: 240 week retrospective multicentre study
A Jayasuriya and others.
Nevirapine vs. efavirenz based treatment in ART naive patients in India: a comparison of immunological response
Kadappa Satish and others.
Can nevirapine warning prevents adverse events in all clinical settings?
A Guelar and others.
Exploring the feasibility of dried blood spots for quantification of lopinavir, nevirapine and efavirenz concentrations
L Else and others.
Nevirapine twice-daily versus once-daily as a simplification strategy after a successful protease inhibitors-based highly active antiretroviral therapy
M Giola and others.
Atazanavir/ritonavir in combination with nevirapine as a nucleoside-sparing strategy in HIV-infected antiretroviral-experienced subjects (NEVATA study)
A M Cattelan and others.
Final safety and efficacy analysis of a randomised pilot study evaluating early versus late switch from efavirenz to nevirapine as part of HAART: the BI Switch Study
M Youle and others.  
Nevirapine use during pregnancy: data from the Italian target cohort
E Chiesa and others.
Correlates of risk of nevirapine (NVP) interruption due to liver toxicity (LT)
A Ridolfo and others.
Clinical experience with nevirapine: a cohort analysis
F Maggiolo and others.

 

<— Conference Main Page

Conference
Main Page


FDA-Approved
HIV and AIDS Treatments

Protease Inhibitors
Agenerase
Aptivus
Crixivan
Fortovase
Invirase
Kaletra
Lexiva

Norvir
Prezista

Reyataz
Viracept


Nucleoside / Nucleotide Reverse Transcriptase Inhibitors

Combivir
Epivir
Emtriva
Epzicom
Hivid
Retrovir
Trizivir
Truvada  
Videx
Viread
Zerit
Ziagen


non Nucleoside Reverse Transcriptase Inhibitors
Rescriptor

Sustiva
Viramune

Entry Inhibitors
Fuzeon

Fixed-dose Combinations
Atripla
Combivir
Trizivir
Truvada